bromelain
Phase 2Biologic
bromelain is one of 32 biologic programs targeting Pseudomyxoma Peritonei. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
138 competitors in Periodontitis
#DrugCompanyPhaseTrials
1Peridex
DDexcel Pharma Technologies Ltd.
Phase 3
Acanya
PfizerPhase 3
Curcumin
Merck & Co.Phase 3
Bayer Aspirin
BayerPhase 2
Cysteine Hydrochloride
NovartisPhase 2
Calcium Hydroxide
MMansoura University
Phase 3
Glutamine
SanofiPhase 2
Atorvastatin Calcium
Merck & Co.Phase 2
Calcium Intravenous Infsuion
MMansoura University
Phase 3
Minocycline Hcl
OOraPharma
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Post Operative Pain1 trial
Effect of Bromelain Versus Calcium Hydroxide as an Intracanal Medication on the Intensity of Postoperative Pain and Bacterial Load Reduction in Necrotic Single Rooted Lower Premolars
Unknown status·—·Phase 1·NCT05687760·30 enrolled
Pseudomyxoma Peritonei1 trial
Periodontitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for bromelain. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- IIndiana University